
Home » GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES
GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES
GlaxoSmithKline Plc has signed a deal to licence in a substantial portfolio of tumour-specific antigens from the international
Ludwig Institute for Cancer Research to boost its cancer vaccine portfolio.
The Scotsman
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
08Feb
-
09Feb
-
15Feb
-
16Feb
-
22Feb
-
07Mar